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Summary Introduction BTH1677, a 1,3–1,6 beta-glucan im-
munomodulator, stimulates a coordinated anti-cancer immune
response in combination with anti-tumor antibody therapies.
This phase II study explored the efficacy, pharmacokinetics
(PK), and safety of BTH1677 combined with cetuximab/
carboplatin/paclitaxel in untreated stage IIIB/IV non-small cell
lung cancer (NSCLC) patients.Methods Patients were random-
ized 2:1 to the BTH1677 arm (N=60; BTH1677, 4 mg/kg,
weekly; cetuximab, initial dose 400 mg/m2 and subsequent
doses 250 mg/m2, weekly; carboplatin, 6 mg/mL/min AUC
Key message This randomized Phase II study (N = 90) evaluated the
addition of BTH1677, a novel pathogen-associated molecular pattern
(PAMP) immunotherapy, to anti-tumor antibody and chemotherapy
(cetuximab/carboplatin/paclitaxel) in previously untreated advanced-
stage non-small cell lung cancer (NSCLC) patients. Addition of
BTH1677 improved overall response rates compared to antibody and
chemotherapy alone.
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(area-under-the-curve) by Calvert formula, once each 3-week
cycle [Q3W]); and paclitaxel, 200 mg/m2, Q3W) or Control
arm (N=30; cetuximab/carboplatin/paclitaxel as above).
Carboplatin/paclitaxel was discontinued after 4–6 cycles; pa-
tients who responded or remained stable received maintenance
therapy with BTH1677/cetuximab (BTH1677 arm) or
cetuximab (Control arm). Investigator and blinded central radi-
ology reviews were conducted. Efficacy assessments included
objective response rate (ORR; primary endpoint), disease con-
trol rate, duration of objective response, time-to-progression
and overall survival (OS); safety was assessed by adverse
events (AEs). Potential biomarker analysis for BTH1677 re-
sponse was also conducted. Results Compared to control treat-
ment, the addition of BTH1677 numerically increased ORR by
both investigator (47.8% vs 23.1%; p=0.0468) and central
(36.6% vs 23.1%; p=0.2895) reviews. No other endpoints dif-
fered between arms. PK was consistent with previous studies.
BTH1677 was well tolerated, with AEs expected of the back-
bone therapy predominating. Biomarker-positive patients
displayed better ORR and OS than negative patients.
Conclusions BTH1677 combined with cetuximab/carboplatin/
paclitaxel was well tolerated and improved ORR as first-line
treatment in patients with advanced NSCLC. Future patient
selection by biomarker status may further improve efficacy
ClinicalTrials.gov Identifier: NCT00874848
Keywords Immunotherapy . NSCLC . Cetuximab .
Biomarker . Beta glucan
Introduction
Lung cancer is the second most commonly diagnosed cancer in
both men and women after prostate and breast cancer, respec-
tively [1]. Approximately 85% of all lung cancers consist of
non-small cell lung cancer (NSCLC) and patients usually pres-
ent with locally advanced or metastatic disease at initial diag-
nosis [1]. For years, the first-line standard of care treatment for
advanced NSCLC consisted of platinum-based combination
chemotherapies [2, 3]. Although still a mainstay therapy for
many NSCLC patients [4], advances in understanding the
molecular pathways driving carcinogenesis (e.g., epidermal
growth factor receptor [EGFR] gene mutations and anaplastic
lymphoma kinase [ALK] translocations) led to development of
targeted EGFR tyrosine kinase inhibitors and ALK-directed
therapies that proved superior to chemotherapies for first-line
management of advanced disease in select molecularly-defined
patient subgroups harboring mutations sensitive to these thera-
pies [4, 5]. Several monoclonal antibody (MAb) therapies have
also been developed for first-line treatment of advanced
NSCLC [4], including bevacizumab, which targets vascular
endothelial growth factor (VEGF) [6], cetuximab [7] and
necitumumab [8], both of which target EGFR and, most recent-
ly, pembrolizumab, which targets the programmed death-1
(PD-1) immune checkpoint receptor on cytotoxic T-cells [9].
Additional MAbs approved for second-line therapy, but likely
to soon be front-line therapy, include ramucirumab, an agent
targeting VEGF receptor 2 (VEGFR2) [10], as well as the anti-
PD-1 and anti-programmed death ligand-1 (PD-L1) MAbs,
nivolumab [11] and atezolizumab [12]. Unlike the other
MAbs mentioned above, cetuximab ultimately never achieved
regulatory approval for treatment of NSCLC. However, results
of phase III NSCLC studies with cetuximab in combination
with platinum doublet chemotherapy did show modest im-
provements in clinical efficacy endpoints [13, 14], which led
to National Comprehensive Cancer Network guidelines
recommending treatment of NSCLC with regimens containing
cetuximab in select patients [4].
BTH1677 (β(1,6)-[poly-(1,3)-D-glucopyranosyl]-
poly-β-(1,3)-D-glucopyranose; Imprime PGG; Biothera
Pharmaceuticals Inc., Eagan, MN), is a fungal-derived, wa-
ter-soluble, 1,3–1,6 beta glucan. It is purified from the cell
wall of a proprietary, non-recombinant, strain of the yeast
Saccharomyces cerevisiae and consists purely of D-glucose
molecules joined together via beta 1,3 and 1,6 linkages.
Specifically, it consists of a backbone of 1,3 linked glucose
residues with periodic branches linked to the backbone in a
1,6 configuration. Similar to the backbone, the side chains
also contain multiple 1,3-linked glucose residues. No beta
glucans have been approved for clinical use in the United
States. However, in China and Japan, two fungal mushroom-
derived 1,3–1,6 beta glucans (lentinan and schizophyllan)
have been approved. The chemical structure of BTH1677 is
different from that of mushroom-derived beta glucans which
have a higher branching frequency and side chains that consist
of only single glucose residues [15–17].
BTH1677 functions as a pathogen-associated molecular
pattern (PAMP) molecule to stimulate a coordinated innate
and adaptive anti-cancer immune response in combination
with anti-tumor antibody therapies. When BTH1677 enters
the blood, it is bound by endogenous plasma anti-beta glucan
antibodies (ABA) resulting in complement activation and
opsonization with complement protein iC3b [18, 19]. The
BTH1677/ABA/iC3b complex initially binds to innate
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immune effector cells through complement receptor 3 and Fc
gamma receptor IIA (FcγIIA) [18, 19], activating innate im-
mune cell function and enabling direct killing of antibody-
targeted tumor cells [18]. BTH1677 also enables reeducation
of the tumor microenvironment, shifting the normally sup-
pressive M2-state macrophages to a more M1 (tumor attack)
state [20, 21], and promoting depletion and/or maturation of
myeloid-derived suppressor cells in the tumor microenviron-
ment [22]. BTH1677 treatment additionally activates antigen-
presenting cells, driving co-stimulatory marker expression on
macrophages and dendritic cells, as well as dendritic cell mat-
uration, CD4 and CD8 T-cell expansion, and production of
key anti-tumor cytokines (e.g., interferon gamma) [21,
23–26]. In murine syngeneic and xenogeneic tumor models,
the administration of BTH1677 with various tumor-targeting
monoclonal antibodies has resulted in greater suppression of
tumor growth and longer survival than with either agent alone
[27–29]. One of these studies [28] specifically evaluated
BTH1677 and cetuximab in a lung cancer model. Similar
effects have been observed with BTH1677 combined with
anti-angiogenic antibodies (anti-VEGF and anti-VEGFR2)
[22, 30, 31] and checkpoint inhibitor antibodies [32, 33].
Clinically, in healthy subjects, BTH1677was well tolerated
after single doses up to 6 mg/kg and after 7 daily doses up to
4 mg/kg and pharmacokinetic (PK) parameters demonstrated
linearity with dose [34]. Additionally, BTH1677 in combina-
tion with cetuximab, with or without irinotecan, was well
tolerated with promising evidence of efficacy in a phase Ib/II
study in patients with recurrent or progressive metastatic co-
lorectal cancer (mCRC) [35–37].
Based on the preclinical efficacy observed in vivo in
murine lung cancer models with BTH1677 combined with
either cetuximab [28] or bevacizumab [31], parallel studies
were designed to evaluate these BTH1677 combinations in
NSCLC patients. Here we report results of the randomized,
open-label, multicenter, phase II study (NCT00874848) de-
signed to evaluate the antitumor activity, safety, and PK
profile of BTH1677 when combined with cetuximab and
concomitant carboplatin and paclitaxel therapy in patients
with previously untreated, advanced NSCLC. Exploratory
evaluation of the potential use of baseline ABA levels as a
measure of a patient’s ability to respond to BTH1677 is also
presented. At the time this study was initiated, cetuximab
was undergoing regulatory review for first-line use in late-
stage NSCLC patients, with approval anticipated. This an-
ticipation, along with our preclinical and clinical mCRC data
demonstrating enhanced antitumor effects with BTH1677
combined with cetuximab therapy prompted us to evaluate
this combination in NSCLC. Although cetuximab was ulti-
mately not approved and is not currently a standard therapy
for NSCLC, the results of this study nevertheless support the
concept of improved efficacy with the addition of BTH1677
to antitumor antibody therapy.
Materials and methods
Study objectives
The primary objective was to evaluate the objective response
rate (ORR; complete response [CR] + partial response [PR])
in each treatment arm. Secondary objectives included assess-
ment of best response rate (CR, PR, and stable disease [SD]
rates), disease control rate (DCR; CR + PR + SD), duration of
objective tumor response (DOR), time-to-progression (TTP),
and overall survival (OS) in each treatment arm. Safety within
each arm and the PK profile of BTH1677 (BTH1677 arm
only) were also evaluated. Exploratory analysis evaluated cor-
relations between baseline ABA levels and clinical responses.
Patient eligibility
Patients, 18 to 75 years of age, provided written informed
consent, and had histologically or cytologically confirmed
stage IIIB or IV NSCLC according to American Joint
Committee on Cancer (AJCC) Staging v6; measurable disease
as defined by Response Evaluation Criteria in Solid Tumors
(RECIST) v1.0; Eastern Cooperative Oncology Group
(ECOG) performance status (PS) 0 or 1; life expectancy of
>3months; adequate hematologic, renal, and hepatic function;
and use of an effective contraceptive.
Exclusion criteria included prior systemic chemotherapy for
lung cancer; previous radiation therapy to >30% of active bone
marrow or any radiation therapy within 3 weeks of study Day
1; central nervous system metastases; uncontrolled hyperten-
sion; peripheral neuropathy ≥Grade 2; fever >38.5 °C within
3 days of Day 1; active yeast infection; human immunodefi-
ciency virus/acquired immune deficiency syndrome, hepatitis
B, or hepatitis C; connective tissue or autoimmune disease;
previous organ or progenitor/stem cell transplant; history of
myocardial infarction or any other unstable or uncontrolled
heart disease; second malignancy within the previous 5 years
(other than basal cell carcinoma, cervical intra-epithelial neo-
plasm, or curatively treated prostate cancer); known hypersen-
sitivity to baker’s yeast, murine proteins, or Cremophor® EL;
previous exposure to cetuximab or BTH1677; or investigation-
al therapy within 30 days prior to Day 1. Females were also
excluded if they were pregnant or breastfeeding.
Study design and treatment plan
This randomized, open-label, multicenter phase II study was
performed at sites in Germany and the United States and was
conducted in full accordance with the Good Clinical Practice:
Consolidated Guideline approved by the International
Conference on Harmonisation and all other applicable nation-
al and local laws/regulations. All study materials were
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approved by the governing ethics committee or institutional
review board at each site.
The study tested the null hypothesis that the true ORR was
≤30% vs the alternative hypothesis that the true ORR in the
BTH1677 arm was at least 50%. Based on the Simon 2-stage
optimal flexible design [38] it was determined that 60 patients
in the BTH1677 arm would provide 90% power for the hy-
potheses testing at an alpha level of 5%. With 2:1 randomiza-
tion, a sample size of 30 patients was determined for the
Control arm. The first stage enrolled 15 and 7 evaluable pa-
tients in the BTH1677 and Control arms, respectively. Criteria
for progression to the second stage were met and enrollment
continued to the full planned patient numbers.
Patients were dosed in 3-week cycles. On Days 1, 8, and 15
of each cycle, patients in the BTH1677 arm were administered
4mg/kg of BTH1677 (intravenous [IV] over 2 to 4 h, depending
on patient weight and total dose administered). On these same
days, cetuximab was administered to all patients in both arms
(initial IV loading dose of 400 mg/m2 over 120 min and subse-
quent IV doses at 250 mg/m2 over 60 min); in the BTH1677
arm, cetuximab was administered after BTH1677. On Day 2 of
each cycle, IV carboplatin (dosed according to Calvert formula
area under the curve [AUC] of 6 mg/mL/min over 30 min) and
IV paclitaxel (200 mg/m2 over 3 h) were administered to all
patients. Prior to each BTH1677 dosing, all patients were to
receive low-dose corticosteroids and a histamine-1 antagonist
(e.g., 4 mg of dexamethasone orally [PO] and 50 mg of diphen-
hydramine IV). On Day 2 of each cycle, all patients were pre-
medicated with the local clinic’s regimen of corticosteroids and
antihistamines prior to carboplatin and paclitaxel therapy.
Premedication for the Control arm patients was performed ac-
cording to local clinical practice for cetuximab.
Carboplatin and paclitaxel administration continued for at
least four cycles, but could continue for up to six cycles at the
investigator’s discretion. Following completion of their sixth
dosing cycle, patients who experienced a response (CR or PR)
or had remained stable (SD) were eligible to continue on
maintenance therapy receiving BTH1677 and cetuximab
(BTH1677 arm) or cetuximab alone (Control arm).
Study assessments
Safety and tolerability were assessed by adverse events
(AEs; National Cancer Institute Common Terminology for
Adverse Events [CTCAE] v3.0), physical examinations, and
laboratory tests.
Tumor response assessments were based on computed to-
mography (CT) scans performed every other cycle (i.e., at 6-
week intervals). Both investigator and blinded central indepen-
dent radiology reviews were performed. Tumor response was
assessed using a modified RECIST v1.0 criteria in which an
initial response did not require a repeat assessment for confir-
mation. All other RECIST v1.0 criteria remained unmodified.
ABA assessments were performed by prototype enzyme-
linked immunosorbent assays (ELISAs) developed at
Biothera Pharmaceuticals Inc. to detect serum IgG and IgM
ABA [18, 39]. A commercially available pooled human se-
rum was assigned an arbitrary value of IgG or IgM ABA
units per milliliter (relative antibody units/mL; RAU/mL)
and run as a standard curve in each assay to determine test
sample ABA levels. A previous study had shown correlations
between ABA levels and the ability of BTH1677 to activate
complement (as measured by C5a production), bind to neu-
trophils, induce neutrophil surface expression of complement
receptor 3 (CR3), modulate neutrophil activation markers
(CD88 and CD62), and induce production of interleukin-8
(IL-8) when incubated with whole blood samples obtained
from healthy subjects [18, 39]. These effects were consistent-
ly seen in blood with ABA levels above the thresholds of 235
IgG RAU/mL or 330 IgM RAU/mL, but were not seen, or
seen at much lower levels, in blood with ABA levels below
these thresholds [18, 39]. Subjects with ABA levels above the
thresholds were identified as biomarker positive and those
below the thresholds were identified as biomarker negative.
These prospectively defined thresholds from the healthy vol-
unteer study were applied to the NSCLC patient samples to
determine patient ABA biomarker status (ie, positive vs neg-
ative). At the time of this NSCLC study, the importance of
ABA in the mechanism of action of BTH1677 was not
known and the protocol did not include collection of samples
for ABA analysis. However, it was possible to perform ABA
determinations from serum samples remaining from baseline
(pre-dosing) PK samples. Since PK samples were only col-
lected from patients in the BTH1677 arm, biomarker analyses
could be performed only in these patients. Correlation of
ABA status and clinical responses was performed in post-
hoc hypotheses-generating analyses.
Pharmacokinetics
PK assessments for BTH1677 were based on post-dosing
blood samples collected on Day 1 of Cycles 1 and 3.
Samples for BTH1677 trough level assessments were also
obtained before dosing on all other weeks of Cycles 1 and 2.
Serum BTH1677 levels were measured by a beta-glucan spe-
cific ELISA developed at Biothera Pharmaceuticals Inc.
which had a lower limit of detection of 1.2 ng/mL and a limit
of quantitation of 4.7 ng/mL. Serum PK parameters of
BTH1677 were calculated using noncompartmental analysis
(NCA) with NCAmodel 202 (constant infusion dose input) in
WinNonlin® v5.2.
Statistical analysis
The analysis populations for investigator and central radi-
ology tumor assessments, safety and survival analyses,
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and PK analyses are shown by treatment arm in Fig. 1.
The analysis populations for tumor assessments (primary
efficacy populations) were comprised of all randomized
patients who received any amount of cetuximab,
carboplatin, or paclitaxel, with or without BTH1677, and
who had an evaluable baseline CT scan assessment and at
least one evaluable post-baseline CT scan assessment. The
investigator and central radiology review populations
were not identical due to separate assessments of the
above criteria by the two review groups. The safety and
survival populations were comprised of all randomized
patients who received any amount of study drugs. The
PK population was comprised of all patients who had at
least 75% of the PK measurements available for any par-
ticular treatment cycle data set.
Efficacy and safety measures are displayed by treat-
ment arm. Categorical data are presented by n and % for
each category and continuous data are presented by mean
and standard deviation (SD). Kaplan-Meier estimates
were utilized for time-to-event analyses and, where appro-
priate, 95% confidence intervals (CI) are provided.
Comparisons between treatment arms were performed at
a 0.05 level of significance. AEs are summarized by sys-




Between August 2009 and November 2012, 90 patients with
NSCLC were randomized 2:1 to the BTH1677 arm or the
Control arm. As shown in Fig. 1, a total of 88 patients
(BTH1677, N = 59; Control, N = 29) were treated and includ-
ed in the safety and survival analyses. The investigator radi-
ology review population included 46 patients in the BTH1677
arm and 26 patients in the Control arm. The central radiology
review population included 41 patients in the BTH1677 arm
and 26 patients in the Control arm. The primary reason for
patient exclusion from either review population was the ab-
sence of baseline or post-baseline CT scan data. The primary
reason for treatment discontinuation in each arm was tumor
progression (BTH1677, 63.3%; Control, 60.0%).
Patient demographics and disease characteristics at base-
line are shown in Table 1. The BTH1677 and Control arms
were generally similar with regard to race, age, ECOG PS,
disease stage at initial diagnosis, and time from initial tumor
diagnosis. There were more males in the BTH1677 arm
(74.6%) than in the Control arm (58.6%) and the percentage
of patients who received prior radiotherapy was higher in the
Control arm (10.3%) than in the BTH1677 arm (0%).
Patients with NSCLC  
randomly assigned (2:1) 
(N = 90) 
Assigned to BTH1677  N = 60 
Treated    n = 59 
    Not treated   n = 1 
Assigned to Control  N = 30 
Treated   n = 29 
    Not treated   n = 1 
Still receiving treatment     n = 0 
Completed study treatmenta   n = 0 
Discontinued treatment     n = 60 
Reasons for discontinuation from treatment phase 
Disease progression         n = 38 (63.3%) 
    Adverse event     n = 13 (21.7%) 
    Subject decision    n = 7   (11.7%) 
    Otherb      n = 2   (3.3%) 
Alive as of final survival analysis data cutc    n = 1  
Still receiving treatment     n = 0 
Completed study treatmenta   n = 1 
Discontinued treatment     n = 29 
Reasons for discontinuation from treatment phase 
Disease progression         n = 18 (60.0%) 
    Adverse event     n =  2  (6.7%) 
    Subject decision    n =  4  (13.3%) 
    Otherb     n =  5  (16.7%) 
Alive as of final survival analysis data cutc    n = 1  
Included in: 
    Investigator radiology reviewd            n = 26 (86.7%) 
    Central radiology reviewe   n = 26 (86.7%) 
    Safety and survival analyses           n = 29 (96.7%) 
    Pharmacokinetic analysis   n = 0   (0.0%) 
Included in: 
    Investigator radiology reviewd            n = 46 (76.7%) 
    Central radiology reviewe   n = 41 (68.3%) 
    Safety and survival analyses           n = 59 (98.3%) 
    Pharmacokinetic analysis   n = 55 (91.7%) 
Fig. 1 Patient Disposition. aPer protocol, completion of treatment was
defined as patients completing 18 cycles of treatment without progressive
disease; bFor the BTH1677 arm these included lost to follow-up (n = 1)
and never treated (n = 1); For the Control arm these included investigator
decision (n = 2), noncompliance (n = 2), and never treated (n = 1); cFinal
survival analysis was performed approximately 4 years after the random-
ization date of the last patient enrolled into study; dReasons for exclusion
from efficacy analyses related to investigator radiology review in the
BTH1677 arm were no evaluable post-baseline CT scan (n = 14; none
of these patients had a best response of disease progression ie, clinical
progression, reported by the investigator); in the Control arm reasons
were no evaluable baseline and/or post-baseline CT scan (n = 4; none
of these patients had a best response of disease progression (ie, clinical
progression) reported by the investigator); eReasons for exclusion from
efficacy analyses related to central radiology review in the BTH1677 arm
were no evaluable baseline and/or post-baseline CT scan (n = 19; one of
these patients had a best response of disease progression ie, clinical pro-
gression, reported by the investigator); in the Control arm reasonswere no
evaluable baseline and/or post-baseline CT scan (n = 4; none of these
patients had a best response of disease progression (ie, clinical progres-
sion) reported by the investigator)
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Efficacy
Tumor-associated assessments Tumor response assessments
are shown in Table 2. For both investigator and central radi-
ology reviews, ORR for the BTH1677 arm was numerically
increased; however, statistical significance was seen only in
the investigator review. Investigator review ORR for the
BTH1677 and Control arms, respectively, was 47.8% (95%
CI: 32.9, 63.1) and 23.1% (95% CI: 9.0, 43.6) (p = 0.0468)
and central review ORR for the BTH1677 and Control arms,
respectively, was 36.6% (95% CI: 22.1, 53.1) and 23.1%
(95% CI: 9.0, 43.6) (p = 0.2895). In both reviews, all re-
sponses were PR. Taking into account the SD rates, DCRs
were high in both reviews and did not statistically differ be-
tween treatment arms in either review (investigator BTH1677
78.3% [95% CI 63.6, 89.1] vs Control 76.9% [95% CI 56.4,
91.0], p = 1.000; central BTH1677 85.4% [95%CI 70.8, 94.4]
vs Control 80.8% [95%CI 60.6, 93.4], p = 0.7385). The DOR
and TTP also did not differ between treatment arms in either
review. DOR and TTP for the BTH1677 arm vs Control arm
by the investigator review were 3.8 (95% CI: 2.8, 4.2) vs 4.7
(95% CI: 1.4, not estimable) months and 4.3 (95% CI: 3.6,
5.6) vs 4.4 (95% CI: 3.2, 5.9) months, respectively, and by the
central reviewwere 4.4 (95%CI: 2.8, 6.5) vs 4.1 (95%CI: 1.4,
5.4) months and 6.4 (95% CI: 4.3, 8.3) vs 6.0 (95% CI: 4.3,
7.1) months, respectively.
Overall survival The OS Kaplan Meier curves for the
BTH1677 and Control arms are shown in Fig. 2a. The median
OS of patients in the BTH1677 arm was 10.3 months (95%
CI: 8.6, 15.1) compared with 12.4 months (95% CI: 9.3, 17.4)
in the Control arm. No statistical significance in OS was ob-
served between arms (hazard ratio 1.14; 95% CI: 0.67, 2.00;
p = 0.6288).
Exploratory analyses by ABA biomarker status Of the 59
BTH1677 patients in the study, 22 (37.3%) were determined
to be ABA biomarker positive and 37 (62.7%) to be ABA
biomarker negative. In the radiology review populations, there
were 15 biomarker-positive and 31 biomarker-negative pa-
tients in the investigator review population and 13
biomarker-positive and 28 biomarker-negative patients in the
central review population. Based on the investigator review,
compared to ORRs of 23.1% in the Control arm and 47.8% in
the BTH1677 arm, ORR in the biomarker-negative BTH1677
patients was 38.7% (95% CI: 21.8, 57.8; p = 0.2592 vs
Control) and 66.7% in the biomarker-positive BTH1677 pa-
tients (95% CI: 38.4, 88.2; p = 0.0088 vs Control; p = 0.1162
vs BTH1677 biomarker negative). However, based on central
review, compared to ORRs of 23.1% in the Control arm and
36.6% in the BTH1677 arm, ORR in the biomarker-negative
BTH1677 patients was 35.7% (95%CI: 18.6, 55.9; p = 0.3791
vs Control) and 38.5% in the biomarker-positive BTH1677
patients (95% CI: 13.9, 68.4; p = 0.4528 vs Control;
p = 1.000 vs BTH1677 biomarker negative). Survival favored
BTH1677 biomarker-positive patients (Fig. 2a). Compared to
medianOS of 12.4months in the Control arm and 10.3months
in the BTH1677 arm, median OS in the biomarker-negative
BTH1677 patients was 9.2 months (vs Control, HR 1.55 [95%
CI: 0.85, 2.81]; p = 0.1507) and 17.0months in the biomarker-
positive BTH1677 patients (vs Control HR 0.79 [95% CI:
0.39, 1.58]; p = 0.4964; vs biomarker negative, HR 0.48
[95% CI: 0.24, 0.95]; p = 0.0327).
Table 1 Patient demographics and disease characteristics at baseline
(Safety population)
Characteristic BTH1677 (N = 59) Control (N = 29)
Age (years)
Median (range) 58 (38, 78) 65 (41, 71)
Sex, n (%)
Male 44 (74.6) 17 (58.6)
Female 15 (25.4) 12 (41.4)
Race, n (%)
White 56 (94.9) 29 (100.0)
Black 2 (3.4) 0
Other 1 (1.7) 0
ECOG performance status, n (%)
0 20 (33.9) 10 (34.5)
1 38 (64.4) 18 (62.1)
Missing 1 (1.7) 1 (3.4)
Disease stage at initial diagnosis, n (%)a
IIIB 3 (5.1) 4 (13.8)
IV 56 (94.9) 25 (86.2)
Histology type, n (%)
Squamous 16 (27.1) 11 (37.9)
Non-squamous 42 (71.2) 18 (62.1)
Missing 1 (1.7) 0
Time from initial tumor diagnosis (months)b
Median (range) 0.7 (0.2, 6.5) 0.5 (0, 8.2)c
Prior cancer treatment, n (%)
Radiotherapy 0 3 (10.3)
Surgery 23 (39.0) 13 (44.8)
Chemotherapyd 1 (1.7) 1 (3.4)
ECOG Eastern Cooperative Oncology Group
aAt the time this study was performed, malignant pleural or pericardial
effusions were considered Stage IIIB, however as of the 7th edition of the
Cancer Staging Manual of the American Joint Committee on Cancer this
would be considered Stage IV (ie, by current staging, all patients were
Stage IV)
b Time from initial tumor diagnosis (months) = screening visit – initial
tumor diagnosis date)/30
c Based on N = 28
dOne patient in the BTH1677 arm received prior chemotherapy for Non-
Hodgkin’s lymphoma and 1 patient in the Control arm received radio-
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































All patients receiving any treatment (BTH1677N = 59; Control
N = 29) were included in the safety population and all of these
patients experienced at least 1 AE (Table 3). In the BTH1677
arm, 44.1% and 28.8% of the patients were assessed as having
AEs that were probably or possibly related to BTH1677, re-
spectively. Grade 3 or Grade 4 AEs occurred at a slightly lower
incidence in the BTH1677 arm vs Control arm (78.0% vs
86.2%). However, serious adverse events (SAEs) and AEs
leading to treatment discontinuation occurred at a higher inci-
dence in the BTH1677 arm vs the Control arm (62.7% vs
41.4% and 22.0% vs 6.9%, respectively). SAEs occurring in
more than one patient in the Control arm were neutropenia,
diarrhea, and pulmonary embolism (each occurring in 2 pa-
tients [6.9%]). SAEs occurring in more than one patient in the
BTH1677 arm were pleural effusion (6 patients [10.2%]), pul-
monary embolism (5 patients [8.5%]), and dyspnea and hemop-
tysis (each occurring in 2 patients [3.4%]). AEs leading to
discontinuation in the Control arm were acute myocardial in-
farction and dermatitis (each occurring in 1 patient [3.4%]) and
in the BTH1677 arm were atrial flutter, cardiac failure acute,
tachyarrhythmia, chills, anaphylactic shock, paresthesia, bron-
chospasm, hemoptysis, pleural effusion, pulmonary embolism,
and pulmonary hemorrhage (each occurring in 1 patient [1.7%
each]) and hypersensitivity (occurring in 2 patients [3.4%]).
All AEs occurring in ≥10% of patients in either the
BTH1677 arm or Control arm are presented in Table 4. As
expected from the backbone therapy of cetuximab, carboplatin
and paclitaxel, skin, hematological, gastrointestinal and neuro-
logical AEs occurred frequently in both groups. The difference
in specific AE incidence between treatment groups was
Number of Patients at Risk 
BTH1677 (N = 59) Median 10.3 months (95% CI, 8.6, 15.1) 
Control (N = 29) Median 12.4 months (95% CI, 9.3, 17.4) 
Hazard Ratio (HR) 1.14 (95% CI, 0.67, 2.00;p = 0.6288) 
Number of Patients at Risk 
BTH1677 Biomarker Negative (N = 37) Median 9.2 months (95% CI, 7.8, 12.4) 
BTH1677 Biomarker Positive (N = 22) Median 17.0 months (95% CI, 8.6, 21.6) 
Control (N = 29) Median 12.4 months (95% CI, 9.3, 17.4) 
Biomarker Positive vs Biomarker Negative HR 0.48 (95% CI, 0.24, 0.95;p = 0.0327
Biomarker Positive vs Control HR 0.79 (95% CI, 0.39, 1.58;p = 0.4964) 
Biomarker Negative vs Control HR 1.55 (95% CI, 0.85, 2.81;p = 0.1507) 
a
b
Fig. 2 Overall Survival. The
Kaplan-Meier overall survival
curves from patients in the safety
population are shown by
treatment arm (Fig. 2a) and by
anti-beta-glucan antibody
biomarker status (Fig. 2b). HR,
hazard ratio; CI, confidence
interval
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generally less than 10%, with the exception of neutropenia,
anemia, constipation, pyrexia, white blood cell count decreased,
paresthesia, peripheral sensory neuropathy, cough, dyspnea,
dysphonia, and rash, all of which occurred at a ≥ 10% lower
incidence in the BTH1677 arm vs the Control arm. Only 1 AE,
skin fissures, occurred at ≥10% higher incidence in the
BTH1677 arm vs the Control arm (18.6% vs 6.9%).
For the AEs occurring in ≥10% of patients, the incidence
occurring at Grade 3 or Grade 4 is also shown in Table 4. The
most commonGrade 3 or Grade 4 AEs were hematological, of
which a lower incidence was again seen in the BTH1677 arm
vs the Control arm. Grade 3 or Grade 4 AEs seen exclusively
in the BTH1677 arm were abdominal pain (3.4%), fatigue
(6.8%), hypersensitivity (3.4%), decreased hemoglobin
(6.8%), hypomagnesemia (1.7%), pain in extremity (1.7%),
dysphonia (1.7%), and pleural effusion (5.1%). Grade 3 or
Grade 4 AEs seen exclusively in the Control arm were nausea
(3.4%), diarrhea (10.3%), mucosal inflammation (3.4%),
chest pain (3.4%), pyrexia (3.4%), asthenia (3.4%), white
blood cell count decreased (6.9%), myalgia (3.4%), and back
pain (3.4%). Instances of these events were low, generally
occurring in only 1–2 patients. Evaluation of all AEs and
Grade 3 or Grade 4 AEs by ABA biomarker status did not
demonstrate differences between groups (data not shown).
Seven deaths (6 in the BTH1677 arm; 1 in the Control arm)
were reported in the treatment phase or within 30 days of the
last dose of study medication. Four of the six deaths in the
BTH1677 arm were due to disease progression; the other two
were due to neutropenia/sepsis/acute renal failure (possibly
related to carboplatin and paclitaxel and unlikely related to
BTH1677 and cetuximab) and pleural effusion caused by pre-
viously broken ribs (unlikely related to any treatment). The
one death that occurred in the Control arm was due to disease
progression.
BTH1677 pharmacokinetics
Overall, serum BTH1677 concentration-time profiles were
well characterized and consistent in Cycle 1 and Cycle 3.
All serum concentrations of BTH1677 were above the limit
of quantitation (4.7 ng/mL) in both cycles and mean concen-
trations declined in a multi-exponential manner over time (da-
ta not shown). Table 5 summarizes the BTH1677 PK param-
eters from Cycle 1/Day 1 (N = 52) and Cycle 3/Day 1
(N = 36). The difference between the N for the two cycles
largely reflected patients discontinuing the study between
Cycle 1 and Cycle 3. Geometric mean AUC0–24 values of
BTH1677 were similar in Cycle 1 (362 μg•hr./mL) and
Cycle 3 (396 μg•hr./mL). Geometric mean Cmax values
(44.3 μg/mL and 47.8 μg/mL) and median tmax values
(2.25 h and 2.40 h) were also similar in both Cycle 1 and
Cycle 3, respectively. Cross-cycle comparison of all other
PK parameters (AUC0-last, AUC0-∞, CL, and t1/2) should be
interpreted with caution since there was a difference in the
blood sampling interval between cycles (Cycle 1: 168 h and
Cycle 3: 24 h). The apparent shorter elimination half-life of
BTH1677 in Cycle 3 relative to Cycle 1 (8.46 h and 19.1 h,
respectively) is likely to be representative of a distribution
phase rather than an elimination phase. Overall, the data sug-
gest that exposure to BTH1677 was consistent in both cycles.
BTH1677 levels assessed weekly before dosing through Day
1 Cycle 3, revealed no meaningful accumulation of BTH1677
with weekly dosing. Mean clearance of BTH1677 on Day 1 of
Cycles 1 and 3 (0.477 L/h and 0.696 L/h, respectively) were
consistent with that reported in healthy subjects (0.441 L/h –
0.619 L/h) [34].
Exploratory analyses of PK parameters by biomarker status
revealed no difference between biomarker-positive vs
biomarker-negative patients (data not shown).
Discussion
BTH1677 is a novel PAMP being developed for the treatment
of cancer in combination with tumor-targeted antibodies, as
well as anti-angiogenic and checkpoint inhibitor antibodies. A
previous phase Ib/II study in second- to third-line mCRC pa-
tients evaluated BTH1677 combined with cetuximab and
showed good tolerability with promising efficacy [34–37].
This randomized, open-label, phase II study demonstrated that
Table 3 Overview of safety
outcomes Adverse Events (AEs), n (%) BTH1677 (N = 59) Control (N = 29)
Any AE 59 (100.0) 29 (100.0)
NCI/CTCAE Grade 3 or 4 AEs 46 (78.0) 25 (86.2)
Serious AEs 37 (62.7) 12 (41.4)
BTH1677-related AEs
Probably related 26 (44.1) NA
Possibly related 17 (28.8) NA
AEs leading to treatment discontinuation 13 (22.0) 2 (6.9)
AE adverse events,NCI/CTCAENational Cancer Institute CommonTerminologyCriteria for Adverse Events,NA
not applicable
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Table 4 Any grade adverse events occurring in ≥10% of patients and the incidence of these that were grade 3 or 4 within indicated categories (Safety
population)
BTH1677 (N = 59) Control (N = 29)
Adverse Events (AEs), n (%) All AEs Grade 3 or Grade 4 AEs All AEs Grade 3 or Grade 4 AEs
Number of patients with at least 1 AE 59 (100.0) 46 (78.0) 29 (100.0) 25 (86.2)
Blood and lymphatic system disorders
Neutropenia 22 (37.3) 19 (32.2) 15 (51.7) 14 (48.3)
Leukopenia 13 (22.0) 9 (15.3) 9 (31.0) 9 (31.0)
Anemia 5 (8.5) 3 (5.1) 8 (27.6) 2 (6.9)
Thrombocytopenia 6 (10.2) 2 (3.4) 5 (17.2) 2 (6.9)
Gastrointestinal disorders
Nausea 25 (42.4) 0 12 (41.4) 1 (3.4)
Diarrhea 24 (40.7) 0 9 (31.0) 3 (10.3)
Constipation 11 (18.6) 0 10 (34.5) 0
Vomiting 11 (18.6) 0 5 (17.2) 0
Abdominal pain 6 (10.2) 2 (3.4) 4 (13.8) 0
Stomatitis 4 (6.8) 0 4 (13.8) 0
General disorders and administration site conditions
Fatigue 30 (50.8) 4 (6.8) 17 (58.6) 0
Mucosal inflammation 13 (22.0) 0 6 (20.7) 1 (3.4)
Chest pain 10 (16.9) 0 5 (17.2) 1 (3.4)
Chills 9 (15.3) 2 (3.4) 4 (13.8) 1 (3.4)
Pyrexia 4 (6.8) 0 8 (27.6) 1 (3.4)
Edema peripheral 5 (8.5) 0 5 (17.2) 0
Asthenia 3 (5.1) 0 4 (13.8) 1 (3.4)
Chest discomfort 1 (1.7) 0 3 (10.3) 0
Immune disorders
Hypersensitivity 4 (6.8) 2 (3.4) 3 (10.3) 0
Infections and infestations
Nasopharyngitis 6 (10.2) 0 3 (10.3) 0
Paronychia 6 (10.2) 0 2 (6.9) 0
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White blood cell count decreased 0 0 3 (10.3) 2 (6.9)
Metabolism and nutritional disorders
Decreased appetite 13 (22.0) 1 (1.7) 7 (24.1) 1 (3.4)
Hypokalaemia 6 (10.2) 3 (5.1) 3 (10.3) 1 (3.4)
Hypomagnesemia 6 (10.2) 1 (1.7) 2 (6.9) 0
Musculoskeletal and connective tissue disorders
Myalgia 11 (18.6) 0 6 (20.7) 1 (3.4)
Pain in extremity 10 (16.9) 1 (1.7) 5 (17.2) 0
Bone pain 6 (10.2) 0 5 (17.2) 0
Arthralgia 6 (10.2) 0 4 (13.8) 0
Back pain 5 (8.5) 0 3 (10.3) 1 (3.4)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Tumor pain 2 (3.4) 0 3 (10.3) 0
Nervous system disorders
Polyneuropathy 16 (27.1) 4 (6.8) 9 (31.0) 2 (6.9)
Paresthesia 7 (11.9) 0 9 (31.0) 0
Dizziness 8 (13.6) 0 6 (20.7) 0
Headache 7 (11.9) 0 4 (13.8) 0
Dysgeusia 5 (8.5) 0 5 (17.2) 0
Peripheral sensory neuropathy 0 0 3 (10.3) 0
Psychiatric disorders
Insomnia 7 (11.9) 0 5 (17.2) 0
Respiratory, thoracic and mediastinal disorders
Cough 12 (20.3) 0 11 (37.9) 0
Dyspnea 12 (20.3) 1 (1.7) 10 (34.5) 1 (3.4)
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BTH1677 in combination with cetuximab, carboplatin, and
paclitaxel numerically improved the ORR in patients with
previously untreated, advanced NSCLC by 13%
(p = 0.2895; central review) to 24% (p = 0.0468; investigator
review) beyond the ORR observed in Control patients. No
meaningful changes were observed in other tumor-
associated assessments or survival. Subject numbers were
small for time-to-event assessments and not all randomized
subjects were included in the primary efficacy populations.
Furthermore, large differences in the percentage of patients
censored for some of these assessments in the investigator
(~20%) vs central (~50%) reviews no doubt further clouded
an ability to see consistent meaningful changes.
The population enrolled in this study was similar to the
large BMS099 study (N = 676) evaluating cetuximab and
carboplatin/taxane vs carboplatin/taxane alone as first-line
treatment in advanced NSCLC patients that were not selected
for EGFR expression or KRAS gene status [13]. Our Control
ORRs of 23.1% (both investigator and central reviews) com-
pare similarly to the ORRs of 27.5% (investigator review) and
25.7% (central review) in the BMS099 cetuximab and
carboplatin/taxane arm. In light of our Control ORR
responding as expected, the improved 47.8% (investigator
review) and 36.6% (central review) ORRs observed with the
addition of BTH1677 to the backbone therapy does suggest
further benefit from the addition of BTH1677. However,
whether improved ORR will translate into benefit in more
clinically relevant endpoints such as PFS or OS would require
larger studies powered for such endpoints. Even in the large
BMS099 study, improved ORR did not translate into im-
proved PFS or OS. In the larger FLEX study (N = 1125),
evaluating cetuximab and cisplatin/vinorelbine vs cisplatin/
vinorelbine alone as first-line treatment in selected EGFR-
expressing advanced NSCLC patients [14], the slight im-
provement in ORR (36% vs 29%) was associated with a sta-
tistically significant improvement in OS, but the effect was
very modest (11.3 vs 10.1 months; HR 0.871; p = 0.044).
Interestingly, our findings indicated that ABA level may be
useful as a predictive biomarker for response to BTH1677.
BTH1677 biomarker-positive patients exhibited better OS
than biomarker-negative patients. However, no serum was
available from Control patients for ABA analysis and, there-
fore, key comparisons of BTH1677 biomarker-positive and
biomarker-negative responses to Control biomarker-positive
and biomarker-negative responses could not be performed.
Hence, the possibility that ABA level may be prognostic for
better responders vs predictive of a BTH1677-specific effect
cannot be ruled out. Given the critical role of ABA in facili-
tating the binding of BTH1677 to immune cells [18–22,
39–42] the former seems unlikely; however, controlled studies
are needed to further assess the true contribution of ABA in
Table 5 Summary of BTH1677 pharmacokinetics parameters
Parameters Geometric Mean (CV%)
BTH1677
Cycle 1/Day 1 Cycle 3/Day 1
N 52 36
AUC0–last (μg•hr./mL) 605 (55.3) 396 (38.1)
AUC0–24 (μg•hr./mL) 362 (35.2) 396 (34.8)
AUC0–∞ (μg•hr./mL) 621 (53.1) 416 (30.4)
Cmax (μg/mL) 44.3 (34.9) 47.8 (37.3)
CL (L/h) 0.477 (46.4) 0.696 (32.1)
t1/2 (hr) 19.1 (42.8) 8.46 (23.2)
tmax (hr)* 2.25 (1.97, 4.33) 2.40 (1.93, 4.17)
Vss (L) 6.60 (35.5) 6.48 (39.9)
N number of patients, CV coefficient of variation, AUC(0-last) area under
the plasma concentration-time curve from time 0 to the time of the last
measurable concentration, AUC0–24 area under the plasma concentration-
time curve from time 0 to 24 h, AUC0–∞ area under the plasma
concentration-time curve from time 0 to infinity, Cmax maximum plasma
concentration, CL systemic clearance; t1/2, elimination half-life, tmax time
of maximum concentration, Vss volume of distribution at steady-state
*Median (range)
Table 4 (continued)
BTH1677 (N = 59) Control (N = 29)
Adverse Events (AEs), n (%) All AEs Grade 3 or Grade 4 AEs All AEs Grade 3 or Grade 4 AEs
Dysphonia 6 (10.2) 1 (1.7) 6 (20.7) 0
Epistaxis 7 (11.9) 0 5 (17.2) 0
Pleural effusion 7 (11.9) 3 (5.1) 3 (10.3) 0
Oropharyngeal pain 3 (5.1) 0 3 (10.3) 0
Skin and subcutaneous tissue disorders
Rash 28 (47.5) 2 (3.4) 19 (65.5) 3 (10.3)
Alopecia 22 (37.3) 0 13 (44.8) 0
Dermatitis 12 (20.3) 0 5 (17.2) 0
Pruritus 9 (15.3) 1 (1.7) 4 (13.8) 1 (3.4)
Skin fissures 11 (18.6) 0 2 (6.9) 0
Dry skin 6 (10.2) 0 3 (10.3) 0
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response to BTH1677, as well as to refine the most appropri-
ate ABA thresholds for defining biomarker-positive and
biomarker-negative patients in the cancer population.
In terms of safety, BTH1677 combination therapy was well
tolerated among patients, which was consistent with previous
experience using BTH1677 in combination with cetuximab in
mCRC patients [34–37]. Overall, most AEs were mild or
moderate in severity. Only skin fissures occurred at a 10%
greater incidence in the BTH1677 arm than in the Control
arm (18.6% vs 6.9%).
PK parameters were consistent with those previously ob-
served in healthy volunteers [34], suggesting that neither
cetuximab nor the carboplatin and paclitaxel therapy affected
the PK of BTH1677.
In conclusion, BTH1677 in combination with cetuximab
and concomitant carboplatin and paclitaxel improved ORR
and was well tolerated in patients with previously untreated,
advanced NSCLC. At the time this study was initiated,
cetuximab was undergoing regulatory review for first-line
use in late-stage NSCLC patients, but ultimately never re-
ceived approval. Hence, although the treatment regimen used
here will not proceed to further evaluation, the results of this
study support the concept of improved efficacy with the addi-
tion of BTH1677 to antibody therapy. The NSCLC study run
in parallel with this study, that evaluated BTH1677 combined
with bevacizumab/carboplatin/paclitaxel in non-squamous
late-stage NSCLC patients, also demonstrated promising re-
sults [43], and a NSCLC study of BTH1677 in combination
with pembrolizumab is ongoing (ClinicalTrials.gov
NCT03003468). This novel therapeutic also continues to be
investigated in combination with antibody therapies in
additional oncology clinical trials that also include further
investigation into the possible role of ABA as a predictive
biomarker for response to BTH1677.
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